Intranasal Drug Delivery: A US Market Report
San Jose, California (PRWEB) May 09, 2012
Follow us on LinkedIn – An organ long overlooked, and neglected, the human nose has now stormed into the pharmacological spotlight as the most important drug delivery pathway, viable for treating a host of medical conditions, ranging from flu to erectile dysfunction. Subsequently, intranasal drug delivery has evolved as an important form of drug delivery in the recent years, and is all set to create significant milestones in the pharmaceutical industry, driven largely by its ability to cure local infections and chronic allergies. The popularity and universal acceptance of intranasal drug delivery by doctors and researchers alike is largely due to the proffered potential of the technique’s efficiency in delivering systemic drugs. In addition to treating common ailments, such as nasal congestion, application of intranasal drug administration is expanding to include treatment of allergies, osteoporosis, pain management, vitamin B12 deficiency, smoking cessation, migraines, and nocturnal enuresis. Technology developments in the area of designing dry powder inhalation devices, for instance, are stepping up interest in intranasal drug delivery. Incremental developments effected in the area of powder particle formulation and engineering, and device architecture is helping powder inhalers to fiercely compete with other delivery techniques, which escort active drug agents via the lungs.
Although innovation in the area of nasal delivery devices has been relatively slow, manufacturers are nevertheless waking up to the dire need for sophisticated devices designed specially to meet the unique challenges of systemic delivery. Preservative-free systems, which either filter air that escape into the bottle or prevent air from entering the device, represent an important step forward in device innovation. Presently, a wide gamut of nasal drug delivery equipment and devices are being commercialized in the marketplace, with the most commonplace device types being nasal sprays pumps with metered drug dispensing systems, pipettes, droppers, and squeeze bottles.
Traditional nasal drug delivery devices, such as pipettes and sprays, have been the mainstay of intranasal drug delivery for a long time. However, the devices are not without limitations such as inefficient deposition of therapeutic drug molecules, for instance, nasal inhalers, and sprays result in unwanted deposition of drugs in the lungs. Other limiting factors include – safety, and dose repeatability. Bi-directional nasal drug delivery is perhaps the most important drug delivery technology innovation that promises to offer a pragmatic solution to the drawbacks and pitfalls of the use of nasal sprays. Bi-directional drug delivery is clinically proven to offer efficient and safe nasal administration in multiple modes. Compared to standard nasal sprays that are presently in use, bi-directional nasal device offers two major advantages, namely restricting the entry of smaller particles into the lungs, and enabling easy airflow inside the nose.
Allergic Infections represents the largest therapeutic area of the intranasal drug delivery, as stated by the new market research report on Intranasal Drug Delivery. However, growth in the market would be fuelled by applications in analgesics therapeutic area. Pain management represents an important therapeutic area, wherein intranasal drug delivery has been met with reasonable success. The intranasal route is demonstrated to be as efficient as the intravenous route in delivering pain relieving drugs. Empirical studies reveal adequate pain relief when drugs are administered intranasally. Several intranasal pain management drugs have been developed for treating postoperative pain, chronic and acute pains (arthritis), and migraines. In addition, most of the growth is expected to be derived from new therapeutic applications, such as vaccines. The use of intranasal drug delivery in Vaccinations is projected to witness a compounded annual growth rate of 11.8% during the analysis period.
Major players profiled in the report include Aegis Therapeutics LLC, Alza Corporation, AptarGroup Inc., Archimedes Pharma Limited, AstraZeneca Plc., MedImmune Inc., Bayer Consumer Care, Bespak Plc., GlaxoSmithKline Plc, Ikano Therapeutics Inc., Marina Biotech Inc., Merck & Co., Novartis AG, OptiNose AS, Pfizer Inc., Sanofi, Rexam Plc., Unigene Laboratories, among others.
The research report titled “Intranasal Drug Delivery: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the intranasal drug delivery market in the US, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche market participants. The report provides annual sales estimates and projections for the US intranasal drug delivery products (prescription drugs) for the years 2009 through 2017 by the following therapeutic areas - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/